DGAP-News: MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer
MorphoSys (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today the appointment of Roland Wandeler, Ph.D., as Chief Commercial Officer (CCO) of MorphoSys, effective May 5, 2020.
DGAP-News: MorphoSys AG / Key word(s): Personnel MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer (news with additional features) 21.04.2020 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, April 21, 2020 MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer
"We are delighted to welcome Roland as CCO and new member of the Management Board. Roland brings a wealth of leadership experience, a clear focus on customer and patient needs, and a track record of exceptional execution in leading and growing businesses, both in the U.S. and internationally. We are confident that, together with him, we will successfully launch our lead product tafasitamab, if approved by the FDA," commented Jean-Paul Kress, M.D., CEO and Chairman of the MorphoSys Management Board. Mr. Wandeler added: "I am honored to join the team at MorphoSys at this exciting time, as the Company evolves into a commercial-stage enterprise. Throughout my career, in markets around the world, I have been passionate about building and leading diverse, high-performing teams and driving innovation for patients. With tafasitamab, MorphoSys has a great opportunity to bring a potential new therapy to patients with blood cancer, true to our mission to improve the lives of patients suffering from serious diseases." Mr. Roland Wandeler has more than 15 years of commercial leadership and general management experience in the pharmaceutical and biotechnology industry, with a strong track record of building and leading sizable affiliates and U.S. franchises across multiple therapeutic areas, including oncology and hematology. Prior to MorphoSys, Mr. Wandeler held positions of increasing responsibility at Amgen, Inc., including General Manager Germany in Munich and General Manager Spain & Portugal in Barcelona, before most recently serving as Corporate Vice President and General Manager of Amgen's US Bone Health and Cardiology Business Unit in Thousand Oaks, California. Mr. Wandeler initially joined Amgen in 2006 in strategic planning for its international business. Subsequent highlights include sales and business unit leadership roles in Germany at the time of several launches across therapeutic areas. Mr. Wandeler began his career at Boston Consulting Group (BCG) in Zurich, Switzerland and Los Angeles, California, where he was a core member of BCG's global Healthcare Practice as well as a Member of the Zurich and Los Angeles Management Teams. Dr. Wandeler holds a M.Sc. in Chemical Engineering and a Doctorate in Technical Sciences from ETH Zurich.
About tafasitamab
Additional features: Document: https://eqs-cockpit.com/c/fncls.ssp?u=UWFASNMQMQ Document title: Media release
21.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | [email protected] |
Internet: | www.morphosys.com |
ISIN: | DE0006632003 |
WKN: | 663200 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 1026687 |
End of News | DGAP News Service |
|
1026687 21.04.2020